Treatment of cerebral palsy with botulinum toxin A: Functional benefit and reduction of disability. Three case reports

References

• Ahnert-Hilger G., Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Progress in Neurobiology 1995; 46: 83–96
   PubMed Web of Science ®Google Scholar
• Blasi J., Chapman E. R., Link E., et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993; 365: 160–163
   PubMed Web of Science ®Google Scholar
• Wiegand H., Erdmann G., Wellhoner H. H. 125i-labelled botulinum a neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Archives of Pharmacology 1976; 292: 161–165
   PubMed Web of Science ®Google Scholar
• Greene P., Kang U., Fahn S., et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40: 1213–1218
   PubMed Web of Science ®Google Scholar
• Hesse S., Lucke D., Malezic M., et al. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. Journal of Neurology, Neurosurgery & Psychiatry 1994; 57: 1321–1324
   PubMed Web of Science ®Google Scholar
• Simpson D. M., Alexander D. N., O'Brien C. F., et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306–1310
   PubMed Web of Science ®Google Scholar
• Calderon-Gonzalez R., Calderon-Sepulveda R., Rincon-Reyes M., et al. Botulinum toxin A in the management of cerebral palsy. Pediatric Neurology 1994; 10: 284–288
   Google Scholar
• Chutorian A. M., Root L. Management of spasticity in children with Botulinum-A Toxin. International Pediatrics 1994; 9: 35–43
   Google Scholar
• Corry I. S., Cosgrove A. P., Walsh E. G., et al. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Developmental Medicine and Child Neurology 1997; 39: 185–193
   PubMed Web of Science ®Google Scholar
• Cosgrove A. P. Botulinum toxin in the management of cerebral palsy. European Journal of Neurology 1995; 2: 73–80
   Google Scholar
• Cosgrove A. P., Corry I. S., Graham H. K. Botulinum toxin in the management of the lower limb in cerebral palsy. Developmental Medicine and Child Neurology 1994; 36: 386–396
   PubMed Web of Science ®Google Scholar
• Denislic M., Meh D. Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics 1995; 26: 249–252
   PubMed Web of Science ®Google Scholar
• Gooch J. L., Sandell T. V. Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Archives of Physical Medicine & Rehabilitation 1996; 77: 508–511
   PubMed Web of Science ®Google Scholar
• Heinen F., Korinthenberg R., Tebben V., . Spastische und dystone Bewegungsstörungen: Behandlung mit Botulinum Toxin A. Aktuelle Neuropädiatrie 1993, H. Todt, D. Heinicke, et al. Wehr Ciba-Geigy Verlag. 1994; 95–98
   Google Scholar
• Heinen F., Wissel J., Mall V., et al. Interventionelle Neuropädiatrie: Behandlungsmöglichkeiten mit Botulinum Toxin A. Aktuelle Neuropädiatrie, (in press), 1996
   Google Scholar
• Koman L. A., Mooney J. F., 3., Smith B., et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. Journal of Pediatric Orthopedics 1993; 13: 489–495
   PubMed Web of Science ®Google Scholar
• Koman L. A., Mooney J. F., 3., Smith B. P., et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. Journal of Pediatric Orthopedics 1994; 14: 299–303
   Google Scholar
• Sutherland D. H., Kaufman K. R., Wyatt M. P., et al. Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: a 3-dimensional motion analysis study. Gait & Posture 1996; 4: 269–279
   Google Scholar
• Wall S. A., Chait L. A., Temlett J. A., et al. Botulinum A chemodenervation: a new modality in cerebral palsied hands. British Journal of Plastic Surgery 1993; 46: 703–706
   PubMedGoogle Scholar
• Bohannon R. W., Smith M. B. Interrater reliability of a modified ashworth scale of muscle spasticity. Physical Therapy 1987; 67: 206–207
   PubMed Web of Science ®Google Scholar
• Heinen F., Scheidt C. E., Nickel T., et al. Spasmodic torticollis — a multicenter study on behavioural aspects II: signs, symptoms and course. Behavioural Neurology 1996; 9: 81–88
   PubMed Web of Science ®Google Scholar
• Nickel T., Heinen F., Scheidt C. E., et al. Spasmodic Torticollis — a multicenter study on behavioural aspects III: psychosocial changes and coping. Behavioural Neurology 1996; 9: 25–31
   Google Scholar
• Philipsen A., Heinen F., Korinthenberg R. Psychosoziale Veränderungen unter der Langzeitbehandlung mit Botulinum Toxin A. Aktuelle Neuropädiatrie, (in press), 1996
   Google Scholar
• Scheidt C. E., Heinen F., Nickel T., et al. Spasmodic torticollis — a multicenter study on behavioural aspects IV: psychopathology. Behavioural Neurology 1996; 9: 97–103
   Google Scholar
• Scheidt C. E., Rayki O., Nickel T., et al. Spasmodic torticollis — a multicenter study on behavioural aspects I: introduction and methods. Behavioural Neurology 1996; 9: 25–31
   Google Scholar
• Dutton J. J., Buckley E. G. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988; 95: 1529–1534
   PubMed Web of Science ®Google Scholar
• Tuite P. J., Lang A. E. Severe and prolonged dysphagia complicating Botulinum Toxin A injections for dystonia in Machado-Joseph disease. Neurology 1996; 46: 84–86
   Google Scholar
• Schmidt R. D., Schmidt T. W. Infant botulism: a case series and review of the literature. Journal of Emergency Medicine 1992; 10: 713–718
   Google Scholar
• Schreiner S. M., Field E., Ruddy R. Infant botulism: a review of 12 years' experience at the children's hospital of Philadelphia. Pediatrics 1991; 87: 159–165
   Web of Science ®Google Scholar
• Troillet N., Praz G. Epidemic of type b botulism: Sion, December 1993 — January 1994. Schweizerische Medizinische Wochenschrift 1995; 125: 1805–1812
   PubMedGoogle Scholar